Detalles de la búsqueda
1.
Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer.
N Engl J Med
; 390(9): 819-829, 2024 Feb 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38416430
2.
Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial.
Oncologist
; 28(9): 799-803, 2023 09 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37226534
3.
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.
JAMA
; 327(20): 1963-1973, 2022 05 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608580
4.
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer.
Pharmacogenet Genomics
; 31(1): 1-9, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32649577
5.
The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1.
Breast Cancer Res
; 21(1): 47, 2019 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30944027
6.
Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer.
Pharmacogenet Genomics
; 29(8): 183-191, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31211741
7.
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).
Breast Cancer Res Treat
; 169(3): 537-548, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29455298
8.
TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor κB p65: Single Nucleotide Polymorphism and Estrogen Dependence.
J Pharmacol Exp Ther
; 365(3): 700-710, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29592948
9.
TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor-κB Activation: Single-Nucleotide Polymorphism- and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune Response.
Mol Pharmacol
; 92(2): 175-184, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28615284
10.
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
Cancer
; 123(13): 2444-2451, 2017 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28464211
11.
Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32.
Breast Cancer Res Treat
; 164(2): 371-378, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28447237
12.
Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.
Breast Cancer Res
; 18(1): 1, 2016 Jan 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-26728744
13.
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
Breast Cancer Res Treat
; 156(2): 343-9, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27006189
14.
Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
Breast Cancer Res Treat
; 157(1): 101-8, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27116182
15.
ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.
N Engl J Med
; 366(5): 399-408, 2012 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-22149921
16.
Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy.
Breast Cancer Res Treat
; 153(1): 135-44, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26208483
17.
Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.
Breast Cancer Res Treat
; 153(2): 353-60, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26276354
18.
Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
Breast Cancer Res Treat
; 149(2): 439-48, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25552364
19.
Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer.
Breast Cancer Res Treat
; 150(3): 605-11, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25833209
20.
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Lancet Oncol
; 15(4): 474-82, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24636210